ГЕНЫ-КАНДИДАТЫ РЕЗИСТЕНТНОСТИ К АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЕ И ИХ СВЯЗЬ С РИСКОМ РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТЫХ КАТАСТРОФ
https://doi.org/10.15829/1728-8800-2013-1-67-72
Аннотация
В обзоре представлены современные данные мировой литературы о наиболее вероятных полиморфизмах генов резистентности к аспирину. Таких как: полиморфизмы циклооксигеназы, гликопро- теинов GP Ib/IIIa, GP Ibα, GP VI аденозиндифосфат рецепторов P2Y1, P2Y12. Рассмотрена частота распространения полиморфизмов при лабораторной аспирин-резистентности, связь данных полиморфизмов с развитием неблагоприятных сердечно-сосудистых событий на фоне приема аспирина.
Об авторах
Ю. И. Гринштейн
ГБОУ ВПО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого Минздрава России», Красноярск
Россия
Россия
доктор медицинских наук, профессор, заведующий кафедрой терапии ИПО
Тел.: 8 (391) 2642718
А. А. Косинова
ГБОУ ВПО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого Минздрава России», Красноярск
Россия
аспирант кафедры
Россия
аспирант кафедры
И. Ю. Гринштейн
ГБОУ ВПО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого Минздрава России», Красноярск
Россия
кандидат медицинских наук, докторант кафедры поликлинической терапии
Россия
кандидат медицинских наук, докторант кафедры поликлинической терапии
Список литературы
1. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849–60.
2. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336: 195–8.
3. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events. Arch Intern Med 2007; 167 (15): 1593–9.
4. Petreñas CL, Yubero GC. Resistance to aspirin: Prevalence, mechanisms of action and association with thromboembolic events. A narrative review. Farm Hosp 2010; 34 (1): 32–43.
5. Dussaillant G, Zapata M, Fardella P, et. al. Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients. Rev Med Chile 2005; 133 (4): 409–17.
6. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326 (7380): 82–3.
7. Feher G, Koltai K, Papp E, et. al. Aspirin resistance: Possible roles of cardiovascular risk factors, previous disease history, c oncomitant medications and haemorrheological variables. Drugs Aging 2006; 23: 559–67.
8. Catella-Lawson F, Reilly M, Kapoor SC, et. al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med 2001; 345: 1809–17.
9. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606–17.
10. Mansour K, Taher AT, Musallam KM, et al. Aspirin Resistance. Adv. Hematol 2009; PMID: 19960045.
11. Deliargyris EN, Boudoulas H. Aspirin Resistance. Hellenic J Cardiol 2004; 45: 1–5.
12. Mangalpally KK, Siqueiros-Garcia A, Vaduganathan M, et al. Platelet activation patterns in platelet size sub-populations: differential responses to aspirin in vitro. J Thromb Thrombolysis 2010; 30 (3): 251–62.
13. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. JACC 2008; 52 (9): 743–9.
14. Kunicki TJ, Williams SA, Nugent DJ, et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101 (1): 123–33.
15. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008: 66 (2): 222–32.
16. Frelinger AL, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 2888–96.
17. Meen O, Brosstad F, Khiabani H, et al. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest 2008; 68 (3): 185–91.
18. Takahashi S, Ushida M, Komine R, et al. Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008; 121 (4): 509–17.
19. Pettinella C, Romano M, Stuppia L, et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 2009; 101 (4): 687–90.
20. Clappers N, Oijen MG, Sundaresan S, et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 2008; 100 (1): 70–5.
21. Andrioli G, Minuz P, Solero P, et al. Defective platelet response to arachidonic acid and thromboxane A (2) in subjects with Pl (A2) polymorphism of beta (3) subunit (glycoprotein IIIa). Br J Haematol 2000; 110: 911–8.
22. Cooke GE, Liu-Stratton Y, Ferketich AK, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. JACC 2006; 47: 541–6.
23. Lepantalo A, Mikkelsson J, Resendiz JC, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253–9.
24. Lim E, Carballo S, Cornelissen J, et al. Dose-related efficacy of aspirin after coronary surgery in patients with Pl (A2) polymorphism (NCT00262275). Ann Thorac Surg 2007; 3: 134–8.
25. Dropinski J, Musial J, Sanak M, et al. Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thromb Res 2007; 119: 301–3.
26. Morawski W, Sanak M, Cisowski M, Szczeklik M, et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005; 130: 791–6.
27. Stepien E, Szuldrzynski K, Branicka A, et al. The thrombin generation is associated with the PIA1/A2 beta3, integrin polymorphism in aspirin-treated patients with coronary artery disease: a role of statins. Pol Arch Med Wewn 2007; 117: 33–40.
28. Undas A, Brummel K, Musial J, et al. Pl (A2) polymorphism of beta (3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666–72.
29. Fontana P, Nolli S, Reber G, et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 4: 813–9.
30. Lev EI, Patel RT, Guthikonda S, et al. Genetic polymorphisms of the platelet receptors P2Y (12), P2Y (1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119 (3): 355–60.
31. Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract 2007; 61: 826–34.
32. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702–8.
33. Abderrazek F, Chakroun T, Addad F, et al. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb Res 2010; 125 (6): 265–8.
34. Syros G, Mehran R, Weisz G, et al. Role of PLA2 polymorphism on clinical events after percutaneous coronary intervention. Acute Card Care 2009; 11 (2): 88–91.
35. Le Hello C, Morello R, Lequerrec A, et al. Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting. Thromb J 2007; 5: 19.
36. Su G, Wang Z, Ding Y. Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong. Univ. Sci. Technolog. Med. Sci. 2007; 27 (6): 664–7.
37. Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 2008; 196 (1): 341–8.
38. Zytkiewicz M, Giełwanowska L, Wojtasińska E, et al. Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn 2008; 118 (12): 727–33.
39. Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36 (2): 276–80.
40. Pamukcu B, Oflaz H, Onur I, et al. Impact of genetic polymorphisms on platelet function and aspirin resistance. Blood Coagul Fibrinolysis 2010; 21 (1): 53–6.
41. Bernardo E, Angiolillo DJ, Ramírez C, et al. Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006; 17 (8): 586–90.
42. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thrombosis research 2005; 116 (6): 491–7.
43. Godeneche G, Sorel N, Ragot S, et al. Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate. Platelets 2009; 20 (7): 471–7.
44. Khaspekova SG, Sirotkina OV, Shimanova IV, et al. Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action. Biomed Khim 2008; 54 (3): 361–71.
45. Agúndez JA, Martínez C, Pérez-Sala D, et al. Pharmacogenomics in aspirin intolerance. Curr Drug Metab 2009; 10 (9): 998–1008.
46. Jin YY, Yu GZ, Wang Y, et al. Variable number of tandem repeats polymorphism of platelet glycoprotein Ib alpha in Chinese people and CC genotype with aspirin sensitivity in patients with cerebral infarction. J Clin Pharm Ther 2009; 34 (2): 239–43.
47. Li Q, Chen BL, Ozdemir V, et al. H. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007; 8 (6): 577–86.
48. Herrera-Galeano JE, Becker DM, Wilson AF, et al. A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene is Associated with Increased Platelet Aggregabili. Arterioscler Thromb Vasc Biol 2008; 28 (8): 1484–90.
49. McCaslin J, Ashour H, Bhattacharya V, et al. Increased platelet-monocyte aggregation in male claudicants with the Pl (A1/A2) polymorphism of Gp IIb/IIIa. Eur J Vasc Endovasc Surg 2008; 36 (2): 132–7.
Рецензия
Для цитирования:
Гринштейн Ю.И., Косинова А.А., Гринштейн И.Ю. ГЕНЫ-КАНДИДАТЫ РЕЗИСТЕНТНОСТИ К АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЕ И ИХ СВЯЗЬ С РИСКОМ РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТЫХ КАТАСТРОФ. Кардиоваскулярная терапия и профилактика. 2013;12(1):67-72. https://doi.org/10.15829/1728-8800-2013-1-67-72
For citation:
Grinshtein Yu.I., Kosinova A.A., Grinshtein I.Yu. ASPIRIN RESISTANCE CANDIDATE GENES AND THEIR ASSOCIATION WITH THE RISK OF CARDIOVASCULAR EVENTS. Cardiovascular Therapy and Prevention. 2013;12(1):67-72. (In Russ.) https://doi.org/10.15829/1728-8800-2013-1-67-72
Просмотров:
599
Послать статью по эл. почте 
